Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $7M fell 33.3% year over year, ahead of the -37.6% change in trailing-twelve-month research & development. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at -19.5% a year.

Context

  • Research & development amounted to 47.9% of revenue in FY2025.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -37.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7M+11.2% QoQ
Last fiscal yearDec 2025
$33.56M-34.6% YoY
LTMMar 2026
$30.06M-37.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.3%——
1 year-34.6%——
3-year CAGR-19.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
33.56M USD
Year-over-year change
-34.6%
4-year CAGR
-23.3%

Research & Development vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.6% is the 10th highest of 11, against a peer median of -15.1%.
  • Over three fiscal years its annual growth of -19.5% compares with a peer median of +1.3%.
BDTX Competitors
Research & Development for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B USD+22061.7%+5.1%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M USD-28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M USD-9.4%-6.8%290.9%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M USD-24.6%-10.1%27721.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M USD+141.5%+89.7%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$30.06M USD-37.6%-19.5%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M USD-28.8%-2.5%181.7%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$205K USD-48.5%-58.6%0.4%
Peer median (excluding BDTX) —-15.1%+1.3%567.3%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.